vs
ATI INC（ATI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ATI INC的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 10.3%，领先2.5%），Revvity同比增速更快（5.9% vs 0.6%），Revvity自由现金流更多（$161.8M vs $74.6M），过去两年Revvity的营收复合增速更高（9.0% vs 2.5%）
ATI是加拿大半导体科技企业，总部位于安大略省万锦市，专注于图形处理器（GPU）及芯片组研发。公司成立于1985年，1993年公开上市，2006年被AMD收购。作为无晶圆厂半导体巨头，ATI坚持自主研发，生产组装环节外包，2000年竞争对手3dfx破产后，成为全球图形芯片领域的核心厂商之一。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ATI vs RVTY — 直观对比
营收规模更大
ATI
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出5.2%
0.6%
净利率更高
RVTY
高出2.5%
10.3%
自由现金流更多
RVTY
多$87.2M
$74.6M
两年增速更快
RVTY
近两年复合增速
2.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $118.2M | $98.4M |
| 毛利率 | 22.8% | — |
| 营业利润率 | 14.2% | 14.5% |
| 净利率 | 10.3% | 12.7% |
| 营收同比 | 0.6% | 5.9% |
| 净利润同比 | 21.9% | 3.9% |
| 每股收益（稀释后） | $0.85 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATIRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润ATIRVTY
| Q1 26 | $118.2M | — | ||
| Q4 25 | $96.6M | $98.4M | ||
| Q3 25 | $110.0M | $46.7M | ||
| Q2 25 | $100.7M | $53.9M | ||
| Q1 25 | $97.0M | $42.2M | ||
| Q4 24 | $137.1M | $94.6M | ||
| Q3 24 | $82.7M | $94.4M | ||
| Q2 24 | $81.9M | $55.4M |
毛利率ATIRVTY
| Q1 26 | 22.8% | — | ||
| Q4 25 | 23.2% | — | ||
| Q3 25 | 22.7% | 53.6% | ||
| Q2 25 | 21.3% | 54.5% | ||
| Q1 25 | 20.6% | 56.5% | ||
| Q4 24 | 21.2% | — | ||
| Q3 24 | 21.4% | 56.3% | ||
| Q2 24 | 20.8% | 55.7% |
营业利润率ATIRVTY
| Q1 26 | 14.2% | — | ||
| Q4 25 | 14.5% | 14.5% | ||
| Q3 25 | 14.4% | 11.7% | ||
| Q2 25 | 14.1% | 12.6% | ||
| Q1 25 | 12.8% | 10.9% | ||
| Q4 24 | 17.8% | 16.3% | ||
| Q3 24 | 13.5% | 14.3% | ||
| Q2 24 | 13.0% | 12.4% |
净利率ATIRVTY
| Q1 26 | 10.3% | — | ||
| Q4 25 | 8.2% | 12.7% | ||
| Q3 25 | 9.8% | 6.7% | ||
| Q2 25 | 8.8% | 7.5% | ||
| Q1 25 | 8.5% | 6.4% | ||
| Q4 24 | 11.7% | 13.0% | ||
| Q3 24 | 7.9% | 13.8% | ||
| Q2 24 | 7.5% | 8.0% |
每股收益（稀释后）ATIRVTY
| Q1 26 | $0.85 | — | ||
| Q4 25 | $0.70 | $0.86 | ||
| Q3 25 | $0.78 | $0.40 | ||
| Q2 25 | $0.70 | $0.46 | ||
| Q1 25 | $0.67 | $0.35 | ||
| Q4 24 | $0.94 | $0.77 | ||
| Q3 24 | $0.57 | $0.77 | ||
| Q2 24 | $0.58 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $401.7M | $919.9M |
| 总债务越低越好 | $1.8B | — |
| 股东权益账面价值 | $1.9B | $7.3B |
| 总资产 | $5.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.95× | — |
8季度趋势，按日历期对齐
现金及短期投资ATIRVTY
| Q1 26 | $401.7M | — | ||
| Q4 25 | $416.7M | $919.9M | ||
| Q3 25 | $372.2M | $931.4M | ||
| Q2 25 | $319.6M | $991.8M | ||
| Q1 25 | $475.8M | $1.1B | ||
| Q4 24 | $721.2M | $1.2B | ||
| Q3 24 | $406.6M | $1.2B | ||
| Q2 24 | $425.6M | $2.0B |
总债务ATIRVTY
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — |
股东权益ATIRVTY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.9B | $7.6B | ||
| Q4 24 | $1.9B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B |
总资产ATIRVTY
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.1B | $12.2B | ||
| Q3 25 | $5.0B | $12.1B | ||
| Q2 25 | $5.0B | $12.4B | ||
| Q1 25 | $5.2B | $12.4B | ||
| Q4 24 | $5.2B | $12.4B | ||
| Q3 24 | $5.1B | $12.8B | ||
| Q2 24 | $4.9B | $13.4B |
负债/权益比ATIRVTY
| Q1 26 | 0.95× | — | ||
| Q4 25 | 0.95× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | 0.91× | — | ||
| Q4 24 | 0.93× | — | ||
| Q3 24 | 1.04× | — | ||
| Q2 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $74.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.5% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $554.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ATIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $315.8M | $182.0M | ||
| Q3 25 | $229.5M | $138.5M | ||
| Q2 25 | $161.5M | $134.3M | ||
| Q1 25 | $-92.5M | $128.2M | ||
| Q4 24 | $380.9M | $174.2M | ||
| Q3 24 | $24.0M | $147.9M | ||
| Q2 24 | $101.1M | $158.6M |
自由现金流ATIRVTY
| Q1 26 | $74.6M | — | ||
| Q4 25 | $223.1M | $161.8M | ||
| Q3 25 | $167.0M | $120.0M | ||
| Q2 25 | $89.4M | $115.5M | ||
| Q1 25 | $-145.8M | $112.2M | ||
| Q4 24 | $333.6M | $149.8M | ||
| Q3 24 | $-41.8M | $125.6M | ||
| Q2 24 | $40.9M | $136.6M |
自由现金流率ATIRVTY
| Q1 26 | 6.5% | — | ||
| Q4 25 | 19.0% | 21.0% | ||
| Q3 25 | 14.8% | 17.2% | ||
| Q2 25 | 7.8% | 16.0% | ||
| Q1 25 | -12.7% | 16.9% | ||
| Q4 24 | 28.4% | 20.5% | ||
| Q3 24 | -4.0% | 18.4% | ||
| Q2 24 | 3.7% | 19.7% |
资本支出强度ATIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 7.9% | 2.6% | ||
| Q3 25 | 5.6% | 2.6% | ||
| Q2 25 | 6.3% | 2.6% | ||
| Q1 25 | 4.7% | 2.4% | ||
| Q4 24 | 4.0% | 3.4% | ||
| Q3 24 | 6.3% | 3.3% | ||
| Q2 24 | 5.5% | 3.2% |
现金转化率ATIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.27× | 1.85× | ||
| Q3 25 | 2.09× | 2.97× | ||
| Q2 25 | 1.60× | 2.49× | ||
| Q1 25 | -0.95× | 3.03× | ||
| Q4 24 | 2.78× | 1.84× | ||
| Q3 24 | 0.29× | 1.57× | ||
| Q2 24 | 1.23× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATI
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
